TP53 and familial dilated cardiomyopathy: Collectively, these findings establish EA as a promising phytotherapeutic agent against DCM, primarily through ferroptosis inhibition orchestrated by SIRT1/p53 pathway regulation, suggesting its potential role in clinical evaluations for diabetic cardiovascular complications.